Navigation Links
Wyeth's Torisel and Roche/Genentech's Avastin Will Challenge Pfizer's Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
Date:8/19/2007

Increased Survival Rates and Decreased Disease Progression Rates Are the

Advantages, According to a New Report from Decision Resources

WALTHAM, Mass., Aug. 7 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Wyeth's Torisel and Roche/Genentech's Avastin will challenge Pfizer's Sutent as the clinical gold standard for the treatment of metastatic renal cell carcinoma. According to the new report entitled Two Hot New Drugs Battle for Top Position: A Renal Cell Carcinoma Study, both Torisel and Avastin offer increased overall survival rates as well as decreased disease progression times.

"Metastatic renal cell carcinoma is an end-stage disease in which the primary goal of treatment is to prolong survival," said Mohamed Muhsin, analyst at Decision Resources. "Phase III clinical trials have shown Torisel to increase the median overall survival rates of patients by 49 percent. High rates of partial response and stable disease, extended median time to progression, and overall survival rates for patients on Torisel are promising. Phase II trials for Avastin have shown that 61% of patients had stable disease. The median progression-free survival rate was eleven months, and the one-year progression-free survival rates for patients with objective response, minor response, and stable disease were 80%, 57% and 27%, respectively."

About Two Hot New Drugs Battle for Top Position: A Renal Cell Carcinoma Study

Two Hot New Drugs Battle for Top Position: A Renal Cell Carcinoma Study covers the current and future state of the metastatic renal cell carcinoma drug market. The report includes the following:

-- More than 3,000 physician responses that define drug attributes that

drive prescription now and in the future.

* Clinical end point tradeoffs that are most influential to

physicians.

* Areas of unmet need with highest potential.

* Benchmark trial results for specific drug opportunities.

* Patient share potential for emerging therapies and target product

profiles.

-- Decision Resources proprietary analysis of commercial factors that

accelerate or constrain a drug's market potential.

* Promotion: DTC spend, detailing intensity.

* Reimbursement: formulary tier, prior approval restriction, quantity

limits.

* Labeling: black box warnings, approved patient segments,

contraindications.

* Competition: order of entry, pricing, generic entry, pipeline sales

forecast.

* Medical practice: decision trees, treating physician type, line of

therapy.

-- Comparisons of the key clinical attributes of current and emerging

therapies in the areas of efficacy, safety, and delivery.

-- Analysis and supporting data that identifies the clinical "Gold

Standard" now and over the next ten years.

-- Key insights as to which clinical end points have the greatest

influence on physician decision-making.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
2. FDA MedWatch: Avastin (bevacizumab) and Formation of Tracheoesophageal Fistula in a Recent Clinical Study in Patients with Limited-stage Small Cell Lung Cancer
3. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
4. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
5. Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
6. Annual Meeting of the Consortium of Multiple Sclerosis Centers Focuses on the Challenges of Care and Research in Multiple Sclerosis
7. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
8. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
9. Novavax Reports Positive Pre-Clinical Study Results from Live Virus Challenge to Pandemic Flu Vaccine
10. LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic Protection Against Influenza Challenge With Virus-Like Particle Immunization
11. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Arkansas that offers insurance and financial preparation services, is providing an update on ... Rescue organization. , Rock City Rescue is a locally recognized nonprofit that provides ...
(Date:10/13/2017)... Pa. (PRWEB) , ... October 13, 2017 , ... While ... dark poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. ... to medication in darkness or restricted lighting. As such, it eliminates the need to ...
(Date:10/13/2017)... ... October 13, 2017 , ... The ... to promote standards of excellence for the field of eating disorders, announces the ... – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
Breaking Medicine News(10 mins):